QUOTED. Dec. 4, 2018. John Scandurra.
Aria CV hopes to address pulmonary hypertension, a potential devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization. See what Aria CEO John Scandurra said about it here.
"We're on a unique pathway and the potential market is not limited to just pulmonary arterial hypertension, which is the target of drug therapy. We hope that our device can work in other classes of pulmonary hypertension as well, which really opens up into much bigger higher-prevalence markets." –John Scandurra, CEO, Aria CV
- Find out more: Start-Up Spotlight: Aria CV Addresses Right-Heart Failure With Purely Mechanical Solution
Click here for a free trial of Medtech Insight